Explore

ORC

7th International Obesity Research Conference 2023

Los Angeles, United States
1 - 3 March 2023
The conference ended on 03 March 2023

Important Dates

Abstract Submission Deadline
26th October 2020
Early Bird Deadline
17th May 2022
Mid Term Registration
12th December 2022
Late Registration
13th February 2023

About ORC

7th International Obesity Research Conference is the premier international forum to present and discuss the research, developments and new trends in the field of obesity. (ORC-2023) will offer high-quality keynote speakers, a variety of scientific sessions, poster sessions, workshops, symposiums and exhibition booths.

Topics

Nursing in obesity and weight management, Obesity & weight management, Obesity & public health, Childhood obesity, Obesity in women, Obesity & pharmacology, Obesity & diabetes, Obesity & cancer, Obesity & chronic diseases, Health risks associated with obesity, Treatments of obesity, Adolescent obesity, Obesity & nutrition, Obesity

Call for Papers

The abstracts for ORC-2023 can be submitted by completing on the website. Alternatively, you can email your abstract to secretary@obesityanddiseases.com along with these information ( Presenting Author, Email Address, Format for presentation (Oral/Poster), Current Organization with Country, Preferred Session). If the submitted abstract doesn’t follow the guidelines for submission, the abstract will be rejected automatically. The abstract will be reviewed by the committee. We would let you know the committee's decision within 3-5 working days. 

The topics for submission includes:

Pediatric Obesity  Obesity and Physical Activity  Obesity and Pregnancy  Bariatric Surgery  Weight Management  Nursing Care for Obese Patient  Dietary Intervention for Chronic Diseases and Obesity  Comorbidities Associated with Obesity  Medical Devices in Obesity  Drugs in Obesity  Other Aspects of Obesity

Keep Up to Date with PaperCrowd

Sign up and follow your favorite conferences.

We are no longer accepting conference submissions on PaperCrowd. We apologise for any inconvenience.